Gene Based Drug Discovery
The best tips and advice from our vast library of articles, videos, and business tools
Browse Related Topics
Newly Added Articles
- Dallas-Area Trade Show Industry Tries to Ride Out...
- Court halts sale of Findlay, Ohio-based firm's...
- CEO of Tulsa, Okla., Financial Firm Goes to Trial...
- Enterprise Customers Opt for Higher Priced...
- Love of Money Draws Numismatists to Baltimore.
- Computer Worm Gives Scare to Network...
- Family affair as Weston heir takes control of...
Article Archives
1-20 (of 693) related articles
Search Results
|
1-20 (of 693) related articles
Items per page
| |
|
Keryx patents gene-based drug discovery involving
kinase targeted...
Keryx Biopharmaceuticals, Inc. (Jerusalem, Israel; 972 2541 2700) announced that the United States Patent and Trademark Office has ... (PERIODICAL ARTICLE)
Executive Briefing.
News, Trends & Market Intelligence for Instrument Executives Sequenom Acquires Gemini Genomics San Diego, CA and Cambridge, UK ... (PERIODICAL ARTICLE)
Invitrogen Corporation acquires Ethrog Biotechnologies
- new patent...
Invitrogen Corporation (San Diego, CA; 760-603-7200) announced that it has acquired Ethrog Biotechnologies, Ltd. (Israel). Ethrog has developed ... (PERIODICAL ARTICLE)
Schering-Plough exercises option to develop and
commercialize one of Human...
Human Genome Sciences, Inc. (Rockville, MD; 301-309-8504) announced that Schering-Plough Corporation (Madison, NJ) has exercised one of its ... (PERIODICAL ARTICLE)
Bionomics forms epilepsy collaboration with
Emory.
Bionomics Limited (Australia) has strengthened its presence in the United States market. Adding to its list of United ... (PERIODICAL ARTICLE)
Isis license functional genomics patents to
atugen.
atugen AG (Berlin, Germany) and the GeneTrove division of Isis Pharmaceuticals, Inc. (Carlsbad, CA), have entered into an ... (PERIODICAL ARTICLE)
Isis Pharmaceuticals enters into agreement with
Pfizer.
Isis Pharmaceuticals, Inc. (Carlsbad, CA) announced that its GeneTrove division has entered into a target validation agreement with ... (PERIODICAL ARTICLE)
Genta to acquire Salus Therapeutics, expanding
oligonucleotide-based...
Genta, Inc. (Berkeley Heights, NJ) announced that the company has entered into an agreement to acquire Salus Therapeutics, ... (PERIODICAL ARTICLE)
Ingenium licenses Incyte murine model
patents.
Ingenium Pharmaceuticals AG (Munich, Germany) obtained a license from Incyte Genomics, Inc. (Palo Alto, CA) under patents directed ... (PERIODICAL ARTICLE)
Bionomics licenses epilepsy test.
Bionomics Limited (Adelaide, Australia) granted a licence to Boston-based Athena Diagnostics (Boston, MA) to market Bionomics' childhood epilepsy ... (PERIODICAL ARTICLE)
Hybridon obtains patent for second generation
antisense oligonucleotides.
Hybridon, Inc. (Cambridge, MA) announced the issuance of United States Patent 6,608,035 entitled, "Method Of Down-Regulating Gene Expression," ... (PERIODICAL ARTICLE)
Hybridon receives patent for orally administering
second generation...
Hybridon, Inc. (Cambridge, MA) announced the issuance of United States Patent 6,608,035 entitled, "Method Of Down-Regulating Gene Expression," ... (PERIODICAL ARTICLE)
Hybridon receives patent for Protein Kinase A
oligonucleotide.
Hybridon, Inc. (Cambridge, MA) announced the issuance of United States Patent 6,624,293 entitled, "Modified Protein Kinase A-Specific Oligonucleotides ... (PERIODICAL ARTICLE)
Antisense chemistry interference involves
Hybridon.
Hybridon, Inc. (Cambridge, MA) announced that the United States Patent and Trademark Office has declared an interference between ... (PERIODICAL ARTICLE)
Hybridon announces issuance of a patent covering CpG
oligonucleotides.
Hybridon, Inc. (Cambridge, MA) announced the issuance of United States Patent 6,426,334, claiming a novel class of CpG ... (PERIODICAL ARTICLE)
Hybridon patent on novel design of antisense
oligonucleotides.
Hybridon, Inc. (Cambridge, MA; 617-679-5500) announced the issuance of a United States Patent 6,372,427 covering novel design of ... (PERIODICAL ARTICLE)
Hybridon obtains oligonucleotide
patent.
Hybridon, Inc. (Cambridge, MA; 617-679-5500) announced the issuance of United States Patent 6,383,752 claiming a novel class of ... (PERIODICAL ARTICLE)
Ingenium signs INGENOtyping agreement with
SEQUENOM.
Ingenium Pharmaceuticals AG (Munich, Germany) announced that it has signed a research agreement with SEQUENOM, Inc. (San Diego, ... (PERIODICAL ARTICLE)
Ingenium signs INGENOtyping agreement with
SEQUENOM.
Ingenium Pharmaceuticals AG (Munich, Germany) announced that it has signed a research agreement with SEQUENOM, Inc. (San Diego, ... (PERIODICAL ARTICLE)
Eos transfers lead antibody target to
Pharmacopeia.
Pharmacopeia, Inc. (Princeton, NJ; 609-452-3600) and Eos Biotechnology, Inc. (S. San Francisco, CA; 650-246-2302) announced the transfer of ... (PERIODICAL ARTICLE) | |
|
1-20 (of 693) related articles
Items per page
1-20 (of 693) related articles
|
Newsletter Signup 
- Privacy Policy
We Respect Your Privacy Our Privacy Policy outlines our commitment to your privacy and the importance we place on your trust.
Sponsored Links
Site Map | Contact Us | FAQs | About Us | Media Kit | Reprints | RSS Directory | Sign Up for Free Newsletters | Disclosure Policy
Copyright © 1999 - 2008 AllBusiness.com, Inc. All rights reserved.
No part of this content or the data or information included therein may be reproduced,
republished or redistributed without the prior written consent of AllBusiness.com.
Use of this site is governed by our Copyright and Intellectual Property Policy, Terms of Use Agreement and Privacy Policy.
Get In-Depth Company Information from Hoover's | Buy a D&B Credit Report | What is in Your Company's D&B Credit Report? | Article Archives
Online Business Database | Online Business Information | Email Marketing Lists | Sales and Marketing Solutions | Business Mailing Lists
Online Business Database | Online Business Information | Email Marketing Lists | Sales and Marketing Solutions | Business Mailing Lists
Information and opinions on AllBusiness.com solely represent the thoughts and opinions of the authors and are not endorsed by, or reflect the beliefs of,
AllBusiness.com, its parent company D&B, and its affiliates.
AllBusiness.com, its parent company D&B, and its affiliates.
